Bristol-Myers Squibb (BMY): Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb (BMY) maintains a strong reputation in hematology despite patent cliff risks, as illustrated by the PEG ratio. The value of 0.00 captures the level of this metric. The company relies on a powerful R&D center and massive budgets to retain scientists. High clinical trial costs and the acquisition of startups create significant barriers to entry for new players.

Bristol-Myers Squibb Co. - BMY PEG Multiple (period 07/04/2022 - 11/16/2026)

Metric breakdowns and analytics for BMS (BMY)

- share price and consensus valuation forecast:
General company analysis:Bristol-Myers Squibb
Core merchandise of Bristol Myers Squibb Company

The closed-loop treatment cycle and patent protection of Bristol-Myers Squibb (BMY) oncology drugs create a sustainable barrier for competitors, ensuring stable profit dynamics. An analysis of the peg_co ratio allows for a comparison of the current market value of shares with the pace of business expansion: a value below one signals that capital is undervalued relative to growth prospects, which is critical for identifying undervalued assets.